Healthcare

Is Johnson & Johnson’s $1 Billion Pennsylvania Investment a Defining Bet on the Future of Cell Therapy?

New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…

ByByAnuja Singh Mar 1, 2026

Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular Targets with AI-Designed Macrocyclic Peptides?

Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…

ByByAnuja Singh Feb 28, 2026

Can Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?

Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…

ByByAnuja Singh Feb 28, 2026

Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?

Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…

ByByAnuja Singh Feb 28, 2026
Image Not Found

Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race

The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…

ByByAnuja Singh Mar 4, 2026

China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?

China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…

ByByAnuja Singh Mar 4, 2026
Scroll to Top